Stemline Therapeutics Company Profile (NASDAQ:STML)

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.67 (225.09% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016Jefferies GroupReiterated RatingBuy$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016WedbushReiterated RatingOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2015HC WainwrightInitiated CoverageBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.57)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.59)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.41)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.45)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015($0.60)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.58)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014($0.71)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.59)($0.55)($0.57)
Q2 20163($0.56)($0.49)($0.53)
Q3 20163($0.61)($0.54)($0.57)
Q4 20163($0.67)($0.54)($0.61)
Q1 20171($0.55)($0.55)($0.55)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stemline Therapeutics (NASDAQ:STML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
DateHeadline
07/22/16 06:26 PMEarnings Focus and Crowd Sourced Sentiment Review for Stemline Therapeutics, Inc. (NASDAQ:STML) - TGP
07/20/16 09:33 AMToday Stemline Therapeutics Inc Stock Rises - Consumer Eagle
07/20/16 09:33 AMStemline Therapeutics, Inc. (NASDAQ:STML): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 07:36 AMTrading Performance and Target Watch for Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph
07/16/16 09:47 AMIncreased Volatility Noted on Shares of: Stemline Therapeutics, Inc. (NASDAQ:STML) - Engelwood Daily
07/15/16 11:52 AMStemline Therapeutics Inc Upside Stock Momentum at Extreme Strength - CML News
07/14/16 10:12 AMAnalyst Target and Average Rating Watch: Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph
07/14/16 10:12 AMBroker Outlook For Stemline Therapeutics, Inc. (STML) - Fiscal Standard
07/12/16 06:51 PMNew Broker Ratings For Stemline Therapeutics, Inc. (STML) - FTSE News
07/12/16 06:51 PMStemline Therapeutics, Inc. (NASDAQ:STML) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 06:33 PMStemline Therapeutics Inc (NASDAQ:STML) Institutional Investors Quarterly Sentiment - Consumer Eagle
07/08/16 06:35 PMStemline Therapeutics Incorporated (NASDAQ:STML) Short Interest Decreased By 13.29% - Press Telegraph
07/08/16 06:35 PMStemline Therapeutics, Inc. Stock Momentum Hits Strength - CML News
07/05/16 10:28 AMShare Performance Recap for: Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph
07/05/16 10:28 AMBroker Outlook For The Week Ahead Stemline Therapeutics, Inc. (STML) - Fiscal Standard
07/04/16 10:17 AMStemline Therapeutics Incorporated (NASDAQ:STML) Shorted Shares Decreased By 13.29% - Press Telegraph
06/28/16 06:29 PMStemline Therapeutics, Inc. (STML) Broker Price Targets For The Coming Week - Fiscal Standard
06/22/16 06:33 PMStemline Therapeutics, Inc. (NasdaqCM:STML) Stock Momentum Hits Strength - CML News
06/17/16 06:19 PMRecently Issued Stock Ratings For Stemline Therapeutics, Inc. (STML) - Fiscal Standard
06/16/16 11:00 AMStemline Therapeutics, Inc. (STML) - Financial and Strategic SWOT Analysis Review - New Market Study Published
06/11/16 09:34 AMStemline Therapeutics Inc. (STML) Drops 7.81% on June 09 - Equities.com
06/10/16 06:58 PMStemline Therapeutics (STML) Announces SL-401 Phase 2 BPDCN Trial Results to be Presented at EHA
06/10/16 06:58 PMStemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend
06/10/16 11:09 AMStemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend - [at noodls] - June 10, 2016 NEW YORK, June 10, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm ...
06/08/16 09:44 AMStemline Therapeutics Inc. (STML) is Trading Lower on Unusual Volume for June 06 - Equities.com
06/06/16 03:32 PMSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events -
06/06/16 10:39 AMCan Stemline Therapeutics, Inc. (NASDAQ:STML) Keep Up with Analyst Expectations? - Investor Newswire
06/06/16 06:58 AMStemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend's Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO - [at noodls] - June 6, 2016 NEW YORK, June 06, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Jefferies 2016 Healthcare ...
06/06/16 06:30 AMStemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend’s Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO - [GlobeNewswire] - NEW YORK, June 06, 2016-- Stemline Therapeutics, Inc. announced today that Ivan Bergstein, M.D., Stemline’ s CEO, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at ...
06/05/16 08:02 PM9:02 pm Stemline Therapeutics presents Phase 2 data for SL-401 demonstrating 89% overall response rate in BPDCN -
06/04/16 06:18 PMStemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds - [at noodls] - June 4, 2016 NEW YORK, June 04, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially ...
06/04/16 06:07 PMStemline Therapeutics’ SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds - [GlobeNewswire] - NEW YORK, June 04, 2016-- Stemline Therapeutics, Inc. announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid ...
06/03/16 06:15 AMStemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow - [at noodls] - June 3, 2016 NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm ...
06/03/16 06:07 AMStemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow - [GlobeNewswire] - NEW YORK, June 03, 2016-- Stemline Therapeutics, Inc. announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm will be the subject of an oral presentation at ...
06/02/16 07:05 PMStemline Therapeutics, Inc. (STML) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Stemline Therapeutics, Inc. (STML) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Stemline Therapeutics, Inc. (STML). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...Stemline Therapeutics Inc. (STML) is Trading Higher on Unusual Volume for May 30Equities.comStock in Overbought Territory: Stemline Therapeutics, Inc. (NASDAQ:STML)HNNall 3 news articles »
06/02/16 07:05 PMStemline Therapeutics Inc. (STML) Jumps 8.4% on June 02 - Equities.com - Stemline Therapeutics Inc. (STML) Jumps 8.4% on June 02Equities.comStemline Therapeutics Inc. (STML) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 8.4% to $9.17, representing a gain of $0.71 per share. Some 216,261 shares traded hands on 1,627 trades, compared with an ...and more »
06/02/16 09:48 AMStemline Therapeutics Inc. (STML) is Trading Higher on Unusual Volume for May 31 - Equities.com - Analyst RatingsStemline Therapeutics Inc. (STML) is Trading Higher on Unusual Volume for May 31Equities.comStemline Therapeutics Inc. (STML) experienced unusually high volume on May. 31, as the stock gained 6.53% to a closing price of $8.32. The stock saw 387,026 shares trade hands over the course of the day on 2,370 trades. Given that the stock's average ...Broker Changes For Stemline Therapeutics, Inc. (STML)Risers & FallersNext Weeks Broker Price Targets For Stemline Therapeutics, Inc. (STML)Share Trading NewsStemline Therapeutics Incorporated (NASDAQ:STML) Shorted Shares Increased 20.2% After Market SellingHNNall 8 news articles »
06/01/16 09:38 AMGalena Biopharma Inc (NASDAQ:GALE) Rose 4.62%: Stemline Therapeutics, Inc. (NASDAQ:STML), Gold Resource ... - KC Register - Galena Biopharma Inc (NASDAQ:GALE) Rose 4.62%: Stemline Therapeutics, Inc. (NASDAQ:STML), Gold Resource ...KC RegisterStemline Therapeutics, Inc. (NASDAQ:STML) announced that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) was selected for oral presentations at both the upcoming American Society of Clinical Oncology (ASCO) ...
06/01/16 09:38 AMStemline Therapeutics Inc. (STML) Jumps 6.53% on May 31 - Equities.com - Stemline Therapeutics Inc. (STML) Jumps 6.53% on May 31Equities.comStemline Therapeutics Inc. (STML) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 6.53% to $8.32, representing a gain of $0.51 per share. Some 387,026 shares traded hands on 2,370 trades, compared with an ...and more »
05/31/16 07:01 PMStemline Therapeutics Inc. (STML) Jumps 15.02% on May 30 - Equities.com - Stemline Therapeutics Inc. (STML) Jumps 15.02% on May 30Equities.comStemline Therapeutics Inc. (STML) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 15.02% to $7.81, representing a gain of $1.02 per share. Some 276,104 shares traded hands on 1,792 trades, compared with an ...and more »
05/31/16 09:51 AMStock Review and Earnings Check on Stemline Therapeutics, Inc. (NASDAQ:STML) - HNN - Stock Review and Earnings Check on Stemline Therapeutics, Inc. (NASDAQ:STML)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Stemline Therapeutics, Inc.and more »
05/29/16 07:01 PMPerformance at a Glance on Stemline Therapeutics, Inc. (NASDAQ:STML) - HNN - Performance at a Glance on Stemline Therapeutics, Inc. (NASDAQ:STML)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Stemline Therapeutics, Inc. (NASDAQ:STML)'s stock has performed at various points in its past ...and more »
05/27/16 08:02 PMStemline Therapeutics Inc. (STML) Jumps 15.02% on May 27 - Equities.com - Stemline Therapeutics Inc. (STML) Jumps 15.02% on May 27Equities.comStemline Therapeutics Inc. (STML) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 15.02% to $7.81, representing a gain of $1.02 per share. Some 275,615 shares traded hands on 1,790 trades, compared with an ...and more »
05/25/16 03:18 PMSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/24/16 07:24 PMEarnings Review and Stock Rundown for Stemline Therapeutics, Inc. (NASDAQ:STML) - Wall Street Hints and News - Earnings Review and Stock Rundown for Stemline Therapeutics, Inc. (NASDAQ:STML)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Stemline Therapeutics, Inc. (NASDAQ:STML ...and more »
05/21/16 12:13 AMStemline Therapeutics Inc. (STML) Jumps 16.09% on May 20 - Equities.com - Stemline Therapeutics Inc. (STML) Jumps 16.09% on May 20Equities.comStemline Therapeutics Inc. (STML) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 16.09% to $6.35, representing a gain of $0.88 per share. Some 90,268 shares traded hands on 637 trades, compared with an ...and more »
05/19/16 07:32 AMStemline Therapeutics' SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO and EHA Meetings - [at noodls] - May 19, 2016 NEW YORK, May 19, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) ...
05/19/16 06:30 AMStemline Therapeutics’ SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO and EHA Meetings - [GlobeNewswire] - NEW YORK, May 19, 2016-- Stemline Therapeutics, Inc. announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm was selected for oral presentations at both the ...
05/18/16 11:32 AMRevenue Update on Stemline Therapeutics Inc(NASDAQ:STML) - Trade Calls - Revenue Update on Stemline Therapeutics Inc(NASDAQ:STML)Trade CallsStemline Therapeutics Inc(NASDAQ:STML) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $205.65K. Analysts estimated a revenue of $150.00K. Earnings ...Stemline Therapeutics Incorporated (NASDAQ:STML) Sellers Increased By 1.04% Their ShortsThe Postall 2 news articles »
05/17/16 12:04 PMSTEMLINE THERAPEUTICS INC Financials -

Social

About Stemline Therapeutics

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: STML
  • CUSIP:
Key Metrics:
  • Previous Close: $7.33
  • 50 Day Moving Average: $7.26
  • 200 Day Moving Average: $5.77
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $129.26M
  • Beta: 0.18
  • Current Year EPS Consensus Estimate: $-2.23 EPS
  • Next Year EPS Consensus Estimate: $-2.1 EPS
Additional Links:
Stemline Therapeutics (NASDAQ:STML) Chart for Sunday, July, 24, 2016